Compare LXU & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LXU | GERN |
|---|---|---|
| Founded | 1968 | 1990 |
| Country | United States | United States |
| Employees | 513 | 258 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.3M | 808.3M |
| IPO Year | 2006 | N/A |
| Metric | LXU | GERN |
|---|---|---|
| Price | $10.96 | $1.50 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $14.63 | $2.17 |
| AVG Volume (30 Days) | 756.7K | ★ 14.0M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 225.93 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $615,208,000.00 | N/A |
| Revenue This Year | $13.69 | $26.91 |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | $40.41 | ★ N/A |
| Revenue Growth | ★ 17.77 | N/A |
| 52 Week Low | $7.09 | $1.04 |
| 52 Week High | $17.22 | $2.01 |
| Indicator | LXU | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 40.02 | 65.05 |
| Support Level | $10.53 | $1.44 |
| Resistance Level | $15.56 | $1.72 |
| Average True Range (ATR) | 0.37 | 0.09 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 48.02 | 68.06 |
LSB Industries Inc is engaged in the manufacturing and sale of chemical products in the United States. The company manufactures and sells chemical products for the agricultural and industrial sectors. Its products include ammonia, fertilizer grade ammonium nitrate (AN and HDAN), and urea ammonia nitrate (UAN) for agricultural applications; high purity and commercial grade ammonia, sulfuric acids, concentrated, blended, and regular nitric acid, mixed nitrating acids, carbon dioxide, and diesel exhaust fluid for industrial applications; and industrial grade AN (LDAN) and AN solutions for mining applications. Its products are sold through distributors and directly to end customers throughout the United States and other parts of North America.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.